BIOADAPTIVES INC
For the period ended Oct 28, 2024. Filed Oct 30, 2024.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Oct 28, 2024 · Filed Oct 30, 2024
Contents
EX-99.1 · Regarding the Reverse Stock Split
Regarding the Reverse Stock Split
LAS VEGAS, Oct. 29, 2024 (GLOBE NEWSWIRE) -- via IBN -- Due to a website maintenance error, a draft of a letter to BioAdaptives® shareholders was made available on the BioAdaptives® website. While the timing was unfortunate, it raised awareness of an upcoming event critical for the long-term health of BioAdaptives®.
On Jan. 1, 2020, BioAdaptives® had 18,576,379 shares of common stock issued and outstanding. Then, stock was traded for funding to raise money to develop business plans, with the money spent on those plans. Unfortunately, the plans did not work, and the process was repeated until the quarterly report ending June 30, 2024, showed 1,231,728,974 common shares issued and outstanding without increasing revenue. That is roughly a 6,530% increase in shares in less than five years without success in the business plan. For BioAdaptives Inc. to reach just $1.00 per share, the market would have to view BioAdaptives as a $1,213,728,974 company. That number of shares guarantees the stock will remain in the sub-penny range.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.